Scalper1 News
Big biotech Amgen (AMGN) early Monday reported positive interim results from a crucial late-stage trial of blood-cancer drug Kyprolis Monday, helping justify its $10 billion acquisition of Onyx last year. Amgen was up more than 1% in early trading in the stock market today, a modest rise as investors await results from an important second trial. The first trial, called ASPIRE, studied multiple-myeloma patients who’d already relapsed after one Scalper1 News
Scalper1 News